Xenetic Biosciences Inc (XBIO) — Cash Flow-to-Debt Ratio
Xenetic Biosciences Inc (XBIO) has a Cash Flow-to-Debt Ratio of -0.59x as of September 2025, meaning its operating cash flow of $-658.25K could theoretically repay -1% of its total liabilities ($1.11 Million) in one year. See Xenetic Biosciences Inc (XBIO) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Xenetic Biosciences Inc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Xenetic Biosciences Inc across 13 annual periods. Also explore XBIO year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Xenetic Biosciences Inc (2012–2024)
Year-by-year debt coverage analysis for Xenetic Biosciences Inc. For market capitalisation and broader financial context, see Xenetic Biosciences Inc stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.15x | $-2.82 Million | $894.26K | ▲ +38.0% |
| 2023 | -5.08x | $-4.11 Million | $809.59K | ▼ -17.4% |
| 2022 | -4.33x | $-4.65 Million | $1.07 Million | ▼ -29.9% |
| 2021 | -3.33x | $-4.74 Million | $1.42 Million | ▲ +24.7% |
| 2020 | -4.43x | $-4.27 Million | $963.97K | ▼ -199.8% |
| 2019 | -1.48x | $-6.40 Million | $4.33 Million | ▼ -3.2% |
| 2018 | -1.43x | $-6.46 Million | $4.52 Million | ▼ -565.5% |
| 2017 | 0.31x | $1.49 Million | $4.86 Million | ▲ +116.8% |
| 2016 | -1.83x | $-8.79 Million | $4.80 Million | ▼ -255.4% |
| 2015 | -0.51x | $-5.30 Million | $10.30 Million | ▲ +75.6% |
| 2014 | -2.11x | $-12.33 Million | $5.84 Million | ▼ -139.1% |
| 2013 | -0.88x | $-6.05 Million | $6.85 Million | ▲ +35.2% |
| 2012 | -1.36x | $-6.26 Million | $4.59 Million | — |